Alembic Pharmaceuticals Ltd.

NSE: APLLTD BSE: 533573 SECTOR: Pharmaceuticals & Drugs  76k   873   153

651.95
-3.20 (-0.49%)
NSE: Today, 01:14 PM

Price Summary

Today's High

₹ 658.4

Today's Low

₹ 650

52 Week High

₹ 864.05

52 Week Low

₹ 648.3

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

12814.93 Cr.

Enterprise Value

13253.5 Cr.

No. of Shares

19.66 Cr.

P/E

19.02

P/B

2.19

Face Value

₹ 2

Div. Yield

1.53 %

Book Value (TTM)

₹  297.2

CASH

61.22 Cr.

DEBT

499.79 Cr.

Promoter Holding

69.61 %

EPS (TTM)

₹  34.28

Sales Growth

22.23%

ROE

27.33 %

ROCE

26.5%

Profit Growth

21.25 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Alembic Pharmaceuticals Ltd.

Azithral TELLZY ZEET Elena Corazon MEGACARE ZENOM CORIUM GASTRON ENTERON Maxis Ouron

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year22.23%
3 Year19.7%
5 Year10.92%

Profit Growth

1 Year21.25%
3 Year40.7%
5 Year10.96%

ROE%

1 Year27.33%
3 Year28.08%
5 Year26.07%

ROCE %

1 Year26.5%
3 Year25.75%
5 Year26.52%

Debt/Equity

0.0951

Price to Cash Flow

8.63

Interest Cover Ratio

111.931871574002

CFO/PAT (5 Yr. Avg.)

0.960356036379558

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2022 69.61 0
Mar 2022 69.61 0
Dec 2021 69.48 0
Sep 2021 69.48 0
Jun 2021 69.48 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 40.6997343085045% for the Past 3 years.
  • The company has shown a good revenue growth of 19.700542585906% for the Past 3 years.
  • The company has significantly decreased its debt by 1187.24 Cr.
  • Company has been maintaining healthy ROE of 28.0823568802393% over the past 3 years.
  • Company has been maintaining healthy ROCE of 25.7473886014173% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 111.931871574002.
  • The Company has been maintaining an effective average operating margins of 24.6963246123605% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of 1.4405910396315 days.
  • Company has a healthy liquidity position with current ratio of 2.11307033628256.
  • The company has a high promoter holding of 69.61%.

 Limitations

 Looks like the company does not have any serious limitations.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022
Net Sales 1269.69 1189.77 1232.83 1304.31 1160.33
Total Expenditure 995.14 952.82 950.08 1013.01 1033.7
Operating Profit 274.55 236.95 282.75 291.3 126.63
Other Income 4.16 1.71 1.42 11.6 0.62
Interest 2.03 4.41 4.31 5.92 8.7
Depreciation 43.49 44.53 45.34 45.95 46.09
Exceptional Items 0 0 0 0 0
Profit Before Tax 233.19 189.72 234.52 251.03 72.46
Tax 40.5 33.36 40.94 -0.34 0
Profit After Tax 192.69 156.36 193.58 251.37 72.46
Adjusted EPS (Rs) 9.8 7.96 9.85 12.79 3.69

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Net Sales 2985.9 2945.26 3660.28 4132.56 5051.43
Total Expenditure 2353.36 2346.65 2800.98 2940.87 3553.18
Operating Profit 632.54 598.61 859.3 1191.69 1498.25
Other Income 3.28 40.59 25.79 145.96 83.72
Interest 3.21 2.22 14.87 25.19 12.77
Depreciation 82.9 101.76 105.59 135.67 152.6
Exceptional Items 0 0 0 -10 0
Profit Before Tax 549.71 535.22 764.63 1166.79 1416.6
Tax 119.08 113.23 153.42 197.39 241.21
Net Profit 430.63 421.99 611.21 969.4 1175.39
Adjusted EPS (Rs.) 22.85 22.39 32.42 51.43 59.8

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Equity and Liabilities
Share Capital 37.7 37.7 37.7 37.7 39.31
Total Reserves 1829.62 2156.93 2674.71 3308.32 5214.93
Borrowings 0 500 499.3 886.99 199.89
Other N/C liabilities 101 85.07 96.58 192.26 198.59
Current liabilities 658.79 1011.69 1397.76 1453.49 1123.46
Total Liabilities 2627.11 3791.39 4706.05 5878.76 6776.18
Assets
Net Block 799.01 918.3 1085.44 1276.46 1461.18
Capital WIP 347.75 740.64 1106.89 1569.98 1927.63
Intangible WIP 0 0 0 0 0
Investments 103.04 298.89 506.39 833.25 978.25
Loans & Advances 36.53 44.37 14.31 47.71 35.17
Other N/C Assets 0 0 0 0 0
Current Assets 1340.78 1789.19 1993.02 2151.36 2373.95
Total Assets 2627.11 3791.39 4706.05 5878.76 6776.18
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Profit from operations 549.71 535.22 764.63 1166.79 1416.6
Adjustment 84.88 81.9 91.48 30.14 61.78
Changes in Assets & Liabilities -189.44 -188.46 110.38 -460.39 247.36
Tax Paid -117.99 -124.11 -157.69 -196.79 -240.44
Operating Cash Flow 327.16 304.55 808.8 539.75 1485.3
Investing Cash Flow -510.97 -793.58 -753.67 -821.91 -926.47
Financing Cash Flow -96.06 497.8 79.67 166.13 -533.61
Net Cash Flow -279.87 8.77 134.8 -116.03 25.22

Corporate Actions

Investors Details

PARTICULARS Jun 2021% Sep 2021% Dec 2021% Mar 2022% Jun 2022%
Promoters 69.48 69.48 69.48 69.61 69.61
nirayu pvt limit... 26.17 26.17 26.17 26.17 26.17
nirayu limited - - - - -
alembic limited 29.46 29.46 29.46 29.43 29.18
nirayu private l... - - - - -
shreno limited - - - - -
shreno ltd 10.98 10.98 10.98 10.98 10.98
chirayu ramanbhai ... 2.40 2.40 2.40 2.40 2.40
malika chirayu amin 1.59 1.59 1.59 1.59 1.59
uday education soc... - - - - -
pranav chirayu amin 0.54 0.54 0.54 0.54 0.54
udit chirayu amin 0.53 0.53 0.53 0.53 0.53
shaunak chirayu am... 0.53 0.53 0.53 0.53 0.53
vidyanidhi trust 0.43 0.43 0.43 0.43 0.43
bhailal amin gener... - - - - -
arogyavardhini soc... 0.15 0.15 0.15 0.15 0.15
utkarsh vidyakendra 0.08 0.08 0.08 0.08 0.08
ujjwal vidyalaya 0.03 0.03 0.03 0.03 0.03
naintara shaunak a... 0.02 0.02 0.02 0.02 0.02
inaaya shaunak amin 0.02 0.02 0.02 0.02 0.02
ranvir pranav amin 0.02 0.02 0.02 0.02 0.02
samira pranav amin 0.02 0.02 0.02 0.02 0.02
PARTICULARS Jun 2021% Sep 2021% Dec 2021% Mar 2022% Jun 2022%
Investors 30.52 30.52 30.52 30.39 30.39
life insurance cor... - - - - -
icici prudential m... 3.41 3.41 3.39 3.05 2.92
dsp midcap fund - - - - -
hdfc life insuranc... - - - - -
matthews india fund 2.20 2.20 2.20 2.06 1.86
elara india opport... 1.23 1.23 1.24 1.26 1.36
cresta fund limited 1.35 1.35 1.35 1.35 1.35
nomura singapore l... - - - - -
hdfc mutual fund - - - - -
kotak mutual fund - - - - -
iepf - - 0.54 - -
llp - - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Alembic Pharmaceuticals informs about earnings call transcript10 Aug 2022, 2:25PM Alembic Pharma’s arm gets USFDA’s final approval for Adapalene and Benzoyl Peroxide Topical Gel8 Aug 2022, 10:59AM Alembic Pharmaceuticals informs about press release8 Aug 2022, 10:36AM Alembic Pharmaceuticals reports consolidated net loss of Rs 66 crore in Q15 Aug 2022, 11:22AM Alembic Pharma - Quaterly Results4 Aug 2022, 3:46PM Alembic Pharma - Quaterly Results4 Aug 2022, 3:46PM Alembic Pharma - Quaterly Results4 Aug 2022, 3:46PM Alembic Pharmaceuticals’ arm gets USFDA’s nod for Diclofenac Sodium Topical Gel29 Jul 2022, 11:22AM Alembic Pharmaceuticals informs about details of loss of certificate18 Jul 2022, 2:48PM Alembic Pharmaceuticals informs about press release23 Jun 2022, 5:08PM Alembic Pharmaceuticals informs about updates22 Jun 2022, 3:41PM Alembic Pharmaceuticals informs about meeting updates15 Jun 2022, 4:28PM Alembic Pharmaceuticals informs about press release10 Jun 2022, 11:50AM Alembic Pharmaceuticals gets USFDA tentative nod for Dasatinib tablets10 Jun 2022, 11:14AM Alembic Pharmaceuticals gets final nod from USFDA for Pirfenidone Tablets 24 May 2022, 10:46AM Alembic Pharmaceuticals informs about annual secretarial compliance report12 May 2022, 12:01PM Alembic Pharmaceuticals gets USFDA’s final approval for Arformoterol Tartrate Inhalation Solution11 May 2022, 2:30PM Alembic Pharmaceuticals informs about press release11 May 2022, 12:52PM Alembic Pharmaceutical reports 86% fall in Q4 consolidated net profit4 May 2022, 5:46PM Alembic Pharmaceuticals’ arm gets USFDA’s final approval for Docosanol Cream4 May 2022, 10:35AM Alembic Pharma - Quaterly Results2 May 2022, 3:58PM Alembic Pharma - Quaterly Results2 May 2022, 3:58PM Alembic Pharma - Quaterly Results2 May 2022, 3:58PM Alembic Pharmaceuticals’ arm gets final nod for Clobetasol Propionate Foam 25 Apr 2022, 11:12AM Alembic Pharmaceuticals gets USFDA’s approval for Ivabradine Tablets20 Apr 2022, 11:27AM Alembic Pharmaceuticals’ arm gets USFDA’s final approval for Lidocaine and Prilocaine Cream 12 Apr 2022, 10:19AM Alembic Pharmaceuticals gets USFDA’s tentative approval for Dabigatran Etexilate Capsules7 Apr 2022, 11:52AM Alembic Pharmaceuticals acquires balance 40% stake in Aleor Dermaceuticals 29 Mar 2022, 3:52PM Alembic Pharmaceuticals informs about press release21 Mar 2022, 4:00PM Alembic Pharmaceuticals gets USFDA’s approval for Lacosamide Tablets21 Mar 2022, 12:58PM Alembic Pharmaceuticals gets USFDA’s tentative approval for Macitentan Tablets14 Mar 2022, 11:30AM Alembic Pharmaceuticals informs about press release8 Mar 2022, 11:47AM Alembic Pharma’s JV gets USFDA’s final approval for Nystatin and Triamcinolone Acetonide Ointment 8 Mar 2022, 11:40AM Alembic Pharmaceuticals reports 40% fall in Q3 consolidated net profit10 Feb 2022, 6:06PM Alembic Pharma - Quaterly Results10 Feb 2022, 2:14PM Alembic Pharma - Quaterly Results10 Feb 2022, 2:14PM Alembic Pharma - Quaterly Results10 Feb 2022, 2:14PM Alembic Pharma gets USFDA’s nod for Fesoterodine Fumarate Extended-Release Tablets2 Feb 2022, 9:57AM Alembic Pharmaceuticals gets USFDA final approval for Clarithromycin Tablets 1 Feb 2022, 11:44AM Alembic Pharmaceuticals gets USFDA’s tentative approval for Dronedarone Tablets USP10 Jan 2022, 11:26AM Alembic Pharmaceuticals informs about press release7 Jan 2022, 10:37AM Alembic Pharmaceuticals gets USFDA’s tentative approval for Vortioxetine Tablets7 Jan 2022, 9:50AM Alembic Pharmaceuticals gets USFDA’s final approval for Entacapone tablets6 Jan 2022, 2:28PM Alembic Pharmaceuticals informs about press release4 Jan 2022, 12:06PM Alembic Pharmaceuticals gets USFDA’s final nod for Doxycycline Hyclate Delayed release tablets4 Jan 2022, 10:37AM Alembic Pharmaceuticals informs about loss of share certificate 3 Jan 2022, 4:09PM Alembic Pharmaceuticals informs about loss of share certificates13 Dec 2021, 12:59PM Alembic Pharmaceuticals informs about disclosure10 Dec 2021, 4:44PM Alembic Pharmaceuticals makes strategic investment in RIGlmmune10 Dec 2021, 4:40PM Alembic Pharmaceuticals informs about loss of share certificates8 Dec 2021, 4:52PM

Alembic Pharma Stock Price Analysis and Quick Research Report. Is Alembic Pharma an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Alembic Pharma and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 1485.3 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Alembic Pharma has a Debt to Equity ratio of 0.0951 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Alembic Pharma , the EPS growth was 16.2832436594714 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Alembic Pharma has OPM of 29.6599180826024 % which is a good sign for profitability.
     
  • ROE: Alembic Pharma have a healthy ROE of 27.3338247913435 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Alembic Pharma

X